Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jun;67(6):1209–1216. doi: 10.1038/bjc.1993.227

Involvement of basic fibroblast growth factor in suramin-induced inhibition of V79/AP4 fibroblast cell proliferation.

N Bernardini 1, F Giannessi 1, F Bianchi 1, A Dolfi 1, M Lupetti 1, L Citti 1, R Danesi 1, M Del Tacca 1
PMCID: PMC1968483  PMID: 7685616

Abstract

The V79/AP4 Chinese hamster fibroblasts were densely stained with the anti-basic fibroblast growth factor (bFGF) antibody demonstrating an endogenous production of the peptide. The in vitro proliferation of these cells was stimulated by exogenous bFGF and the maximum growth (259% increase in 3H-thymidine incorporation into DNA) was reached with bFGF 10 ng ml-1. Inhibition of bFGF-mediated mitogenic pathway was obtained with a 15-mer antisense oligodeoxynucleotide targeted against bFGF mRNA and with suramin, a drug which blocks the biological activity of heparin-binding growth factors. bFGF antisense oligomer reduced the synthesis of DNA by 79.5 and 89.5% at 20 and 60 microM, respectively; this effect was reversed by the addition of exogenous bFGF to the culture medium. A short-term exposure to suramin 300 micrograms ml-1 produced a modest reduction in 3H-thymidine incorporation but suppressed the mitogenic effect of bFGF on V79/AP4 cells. In cells treated with suramin 300 micrograms ml-1 the drug concentration increased linearly over 3 days, reaching 13.15 micrograms mg-1 of protein; cell proliferation was inhibited in a dose-related manner as evaluated by the colony formation assay (IC50: 344.22 micrograms ml-1) and by the number of mitoses observed in culture. Furthermore, the drug induced ultrastructural alterations, consisting of perinuclear cisternae swelling, chromatin condensation, nucleolar segregation and cytoplasmic vacuolations. These findings demonstrated that the endogenous production of bFGF plays an important role in V79/AP4 fibroblasts proliferation, and the inhibition of bFGF-mediated mitogenic signalling with bFGF antisense oligomer or suramin is an effective mean of reducing cell growth.

Full text

PDF
1209

Images in this article

1211Figure 1
on p.1211
1212Figure 5
on p.1212
1213Figure 6
on p.1213

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaronson S. A. Growth factors and cancer. Science. 1991 Nov 22;254(5035):1146–1153. doi: 10.1126/science.1659742. [DOI] [PubMed] [Google Scholar]
  2. Abraham J. A., Mergia A., Whang J. L., Tumolo A., Friedman J., Hjerrild K. A., Gospodarowicz D., Fiddes J. C. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science. 1986 Aug 1;233(4763):545–548. doi: 10.1126/science.2425435. [DOI] [PubMed] [Google Scholar]
  3. Baldin V., Roman A. M., Bosc-Bierne I., Amalric F., Bouche G. Translocation of bFGF to the nucleus is G1 phase cell cycle specific in bovine aortic endothelial cells. EMBO J. 1990 May;9(5):1511–1517. doi: 10.1002/j.1460-2075.1990.tb08269.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Becker D., Meier C. B., Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J. 1989 Dec 1;8(12):3685–3691. doi: 10.1002/j.1460-2075.1989.tb08543.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bernardini N., Giannessi F., Bianchi F., Dolfi A., Lupetti M., Zaccaro L., Malvaldi G., Del Tacca M. Comparative activity of doxorubicin and its major metabolite, doxorubicinol, on V79/AP4 fibroblasts: a morphofunctional study. Exp Mol Pathol. 1991 Dec;55(3):238–250. doi: 10.1016/0014-4800(91)90004-h. [DOI] [PubMed] [Google Scholar]
  6. Bojanowski K., Lelievre S., Markovits J., Couprie J., Jacquemin-Sablon A., Larsen A. K. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3025–3029. doi: 10.1073/pnas.89.7.3025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bouche G., Gas N., Prats H., Baldin V., Tauber J. P., Teissié J., Amalric F. Basic fibroblast growth factor enters the nucleolus and stimulates the transcription of ribosomal genes in ABAE cells undergoing G0----G1 transition. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6770–6774. doi: 10.1073/pnas.84.19.6770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Culouscou J. M., Garrouste F., Remacle-Bonnet M., Bettetini D., Marvaldi J., Pommier G. Autocrine secretion of a colorectum-derived growth factor by HT-29 human colon carcinoma cell line. Int J Cancer. 1988 Dec 15;42(6):895–901. doi: 10.1002/ijc.2910420618. [DOI] [PubMed] [Google Scholar]
  9. Culouscou J. M., Remacle-Bonnet M., Garrouste F., Marvaldi J., Pommier G. Simultaneous production of IGF-I and EGF competing growth factors by HT-29 human colon cancer line. Int J Cancer. 1987 Nov 15;40(5):646–652. doi: 10.1002/ijc.2910400513. [DOI] [PubMed] [Google Scholar]
  10. De Clercq E. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett. 1979 Nov;8(1):9–22. doi: 10.1016/0304-3835(79)90017-x. [DOI] [PubMed] [Google Scholar]
  11. Dell'Era P., Presta M., Ragnotti G. Nuclear localization of endogenous basic fibroblast growth factor in cultured endothelial cells. Exp Cell Res. 1991 Feb;192(2):505–510. doi: 10.1016/0014-4827(91)90070-b. [DOI] [PubMed] [Google Scholar]
  12. Fantini J., Rognoni J. B., Roccabianca M., Pommier G., Marvaldi J. Suramin inhibits cell growth and glycolytic activity and triggers differentiation of human colic adenocarcinoma cell clone HT29-D4. J Biol Chem. 1989 Jun 15;264(17):10282–10286. [PubMed] [Google Scholar]
  13. Fantini J., Verrier B., Robert C., Pic P., Pichon J., Mauchamp J., Marvaldi J. Suramin-induced differentiation of the human colic adenocarcinoma cell clone HT29-D4 in serum-free medium. Exp Cell Res. 1990 Jul;189(1):109–117. doi: 10.1016/0014-4827(90)90263-a. [DOI] [PubMed] [Google Scholar]
  14. Gospodarowicz D., Ferrara N., Schweigerer L., Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev. 1987 May;8(2):95–114. doi: 10.1210/edrv-8-2-95. [DOI] [PubMed] [Google Scholar]
  15. Hawking F. Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother. 1978;15:289–322. doi: 10.1016/s1054-3589(08)60486-x. [DOI] [PubMed] [Google Scholar]
  16. Hicks K., Friedman B., Rosner M. R. Basic fibroblast-like growth factor is present in the conditioned medium of simian sarcoma virus transformed NRK cells. Biochem Biophys Res Commun. 1989 Nov 15;164(3):1323–1330. doi: 10.1016/0006-291x(89)91814-7. [DOI] [PubMed] [Google Scholar]
  17. Jindal H. K., Anderson C. W., Davis R. G., Vishwanatha J. K. Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases. Cancer Res. 1990 Dec 15;50(24):7754–7757. [PubMed] [Google Scholar]
  18. Kopp R., Pfeiffer A. Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res. 1990 Oct 15;50(20):6490–6496. [PubMed] [Google Scholar]
  19. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  20. La Rocca R. V., Danesi R., Cooper M. R., Jamis-Dow C. A., Ewing M. W., Linehan W. M., Myers C. E. Effect of suramin on human prostate cancer cells in vitro. J Urol. 1991 Feb;145(2):393–398. doi: 10.1016/s0022-5347(17)38351-9. [DOI] [PubMed] [Google Scholar]
  21. La Rocca R. V., Stein C. A., Danesi R., Jamis-Dow C. A., Weiss G. H., Myers C. E. Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab. 1990 Aug;71(2):497–504. doi: 10.1210/jcem-71-2-497. [DOI] [PubMed] [Google Scholar]
  22. La Rocca R. V., Stein C. A., Myers C. E. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells. 1990 Apr;2(4):106–115. [PubMed] [Google Scholar]
  23. Levine A. M., Gill P. S., Cohen J., Hawkins J. G., Formenti S. C., Aguilar S., Meyer P. R., Krailo M., Parker J., Rasheed S. Suramin antiviral therapy in the acquired immunodeficiency syndrome. Clinical, immunological, and virologic results. Ann Intern Med. 1986 Jul;105(1):32–37. doi: 10.7326/0003-4819-105-1-32. [DOI] [PubMed] [Google Scholar]
  24. Li S., Shipley G. D. Expression of multiple species of basic fibroblast growth factor mRNA and protein in normal and tumor-derived mammary epithelial cells in culture. Cell Growth Differ. 1991 Apr;2(4):195–202. [PubMed] [Google Scholar]
  25. Loke S. L., Stein C. A., Zhang X. H., Mori K., Nakanishi M., Subasinghe C., Cohen J. S., Neckers L. M. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci U S A. 1989 May;86(10):3474–3478. doi: 10.1073/pnas.86.10.3474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mahoney C. W., Azzi A., Huang K. P. Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. Differential activation and inhibition of protein kinase C isozymes. J Biol Chem. 1990 Apr 5;265(10):5424–5428. [PubMed] [Google Scholar]
  27. Moscatelli D., Quarto N. Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin. J Cell Biol. 1989 Nov;109(5):2519–2527. doi: 10.1083/jcb.109.5.2519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Myers C., Cooper M., Stein C., LaRocca R., Walther M. M., Weiss G., Choyke P., Dawson N., Steinberg S., Uhrich M. M. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol. 1992 Jun;10(6):881–889. doi: 10.1200/JCO.1992.10.6.881. [DOI] [PubMed] [Google Scholar]
  29. Rifkin D. B., Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol. 1989 Jul;109(1):1–6. doi: 10.1083/jcb.109.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Schweigerer L., Neufeld G., Mergia A., Abraham J. A., Fiddes J. C., Gospodarowicz D. Basic fibroblast growth factor in human rhabdomyosarcoma cells: implications for the proliferation and neovascularization of myoblast-derived tumors. Proc Natl Acad Sci U S A. 1987 Feb;84(3):842–846. doi: 10.1073/pnas.84.3.842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Simi S., Colella C. M., Mariani T., Piras A., Rainaldi G. Qualitative analysis of chromosomal evolution in a colcemid-treated Chinese hamster population. Teratog Carcinog Mutagen. 1988;8(1):45–54. doi: 10.1002/tcm.1770080106. [DOI] [PubMed] [Google Scholar]
  32. Spigelman Z., Dowers A., Kennedy S., DiSorbo D., O'Brien M., Barr R., McCaffrey R. Antiproliferative effects of suramin on lymphoid cells. Cancer Res. 1987 Sep 1;47(17):4694–4698. [PubMed] [Google Scholar]
  33. Stein C. A., LaRocca R. V., Thomas R., McAtee N., Myers C. E. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol. 1989 Apr;7(4):499–508. doi: 10.1200/JCO.1989.7.4.499. [DOI] [PubMed] [Google Scholar]
  34. Sternfeld M. D., Hendrickson J. E., Keeble W. W., Rosenbaum J. T., Robertson J. E., Pittelkow M. R., Shipley G. D. Differential expression of mRNA coding for heparin-binding growth factor type 2 in human cells. J Cell Physiol. 1988 Aug;136(2):297–304. doi: 10.1002/jcp.1041360212. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES